flutamide has been researched along with Obesity in 12 studies
Flutamide: An antiandrogen with about the same potency as cyproterone in rodent and canine species.
Obesity: A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).
| Excerpt | Relevance | Reference |
|---|---|---|
| "The few controlled trials performed so far indicate that the addition of metformin and/or flutamide to a hypocaloric diet in obese women with polycystic ovary syndrome (PCOS) effectively influences different phenotypic aspects of the syndrome." | 9.12 | Treatment with flutamide, metformin, and their combination added to a hypocaloric diet in overweight-obese women with polycystic ovary syndrome: a randomized, 12-month, placebo-controlled study. ( Cacciari, M; Cavazza, C; Gambineri, A; Morselli-Labate, AM; Pagotto, U; Pasquali, R; Patton, L; Vaccina, A, 2006) |
| "Low-dose flutamide-metformin has been developed as a background therapy for non-obese adolescents and young women with hyperinsulinaemic hyperandrogenism, a variant of polycystic ovary syndrome (PCOS)." | 9.11 | Flutamide-metformin plus an oral contraceptive (OC) for young women with polycystic ovary syndrome: switch from third- to fourth-generation OC reduces body adiposity. ( De Zegher, F; Ibáñez, L, 2004) |
| " The objective of this study was to treat aging (7-8 months) +/- follicle-stimulating hormone receptor mice that are destined for reproductive failure with 2 selected antiandrogens, curcumin and flutamide, to counteract deleterious effects of mild hyperandrogenemia on the ovary and metabolism." | 7.75 | Modulation of ovarian structure and abdominal obesity in curcumin- and flutamide-treated aging FSH-R haploinsufficient mice. ( Ram Sairam, M; Tiwari-Pandey, R, 2009) |
| "The authors evaluate the effects of 2 months of treatment with 250 mg flutamide daily on adrenal steroidogenesis (ACTH test) and metabolic parameters (lipids, insulin resistance) in 12 PCOS women aged 33." | 7.72 | Flutamide suppresses adrenal steroidogenesis but has no effect on insulin resistance and secretion and lipid levels in overweight women with polycystic ovary syndrome. ( Dvoráková, K; Hill, M; Stanická, S; Stárka, L; Vondra, K; Vrbíková, J, 2004) |
| "Flutamide treatment was also associated with a trend toward an increase in HDL (by 14%; P = 0." | 5.30 | The effect of a pure antiandrogen receptor blocker, flutamide, on the lipid profile in the polycystic ovary syndrome. ( Diamanti-Kandarakis, E; Duleba, AJ; Mitrakou, A; Raptis, S; Tolis, G, 1998) |
| "The few controlled trials performed so far indicate that the addition of metformin and/or flutamide to a hypocaloric diet in obese women with polycystic ovary syndrome (PCOS) effectively influences different phenotypic aspects of the syndrome." | 5.12 | Treatment with flutamide, metformin, and their combination added to a hypocaloric diet in overweight-obese women with polycystic ovary syndrome: a randomized, 12-month, placebo-controlled study. ( Cacciari, M; Cavazza, C; Gambineri, A; Morselli-Labate, AM; Pagotto, U; Pasquali, R; Patton, L; Vaccina, A, 2006) |
| "Low-dose flutamide-metformin has been developed as a background therapy for non-obese adolescents and young women with hyperinsulinaemic hyperandrogenism, a variant of polycystic ovary syndrome (PCOS)." | 5.11 | Flutamide-metformin plus an oral contraceptive (OC) for young women with polycystic ovary syndrome: switch from third- to fourth-generation OC reduces body adiposity. ( De Zegher, F; Ibáñez, L, 2004) |
| " To distinguish the mechanisms of this association, we determined the interactions of PCO with obesity and the influence of ameliorating direct androgenic actions via short-term treatment with the antiandrogen flutamide." | 5.08 | Insulin sensitivity and antiandrogenic therapy in women with polycystic ovary syndrome. ( Diamanti-Kandarakis, E; Georgiadou, E; Hennes, MM; Hoffmann, RG; Kaklas, N; Kissebah, AH; Mitrakou, A; Platanissiotis, D; Raptis, S; Spina, J, 1995) |
| " This study tested whether 1) in utero cotreatment of prenatally T-treated sheep with androgen antagonist (flutamide) or insulin sensitizer (rosiglitazone) prevents juvenile insulin resistance and adult changes in adipocyte size; and 2) visceral adiposity and insulin sensitivity are both unaltered during early adulthood, confirming the predicted developmental trajectory in this animal model." | 3.83 | Developmental Programming: Impact of Gestational Steroid and Metabolic Milieus on Adiposity and Insulin Sensitivity in Prenatal Testosterone-Treated Female Sheep. ( Beckett, E; Cardoso, RC; Chazenbalk, G; Dumesic, D; Keller, E; Madrigal, V; Moeller, J; Padmanabhan, V; Pease, A; Veiga-Lopez, A, 2016) |
| "The authors evaluate the effects of 2 months of treatment with 250 mg flutamide daily on adrenal steroidogenesis (ACTH test) and metabolic parameters (lipids, insulin resistance) in 12 PCOS women aged 33." | 3.72 | Flutamide suppresses adrenal steroidogenesis but has no effect on insulin resistance and secretion and lipid levels in overweight women with polycystic ovary syndrome. ( Dvoráková, K; Hill, M; Stanická, S; Stárka, L; Vondra, K; Vrbíková, J, 2004) |
| "Hirsutism is the manifestation of hyperandrogenemia in PCOS." | 1.32 | The treatment of polycystic ovary syndrome. ( Ajossa, S; Guerriero, S; Melis, GB; Orrù, M; Paoletti, AM, 2004) |
| "Flutamide treatment was also associated with a trend toward an increase in HDL (by 14%; P = 0." | 1.30 | The effect of a pure antiandrogen receptor blocker, flutamide, on the lipid profile in the polycystic ovary syndrome. ( Diamanti-Kandarakis, E; Duleba, AJ; Mitrakou, A; Raptis, S; Tolis, G, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (25.00) | 18.2507 |
| 2000's | 7 (58.33) | 29.6817 |
| 2010's | 2 (16.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ibáñez, L | 2 |
| Ong, KK | 1 |
| López-Bermejo, A | 1 |
| Dunger, DB | 1 |
| de Zegher, F | 2 |
| Cardoso, RC | 1 |
| Veiga-Lopez, A | 1 |
| Moeller, J | 1 |
| Beckett, E | 1 |
| Pease, A | 1 |
| Keller, E | 1 |
| Madrigal, V | 1 |
| Chazenbalk, G | 1 |
| Dumesic, D | 1 |
| Padmanabhan, V | 1 |
| Tiwari-Pandey, R | 1 |
| Ram Sairam, M | 1 |
| Gambineri, A | 3 |
| Pagotto, U | 3 |
| Tschöp, M | 1 |
| Vicennati, V | 1 |
| Manicardi, E | 1 |
| Carcello, A | 1 |
| Cacciari, M | 3 |
| De Iasio, R | 1 |
| Pasquali, R | 3 |
| Pelusi, C | 1 |
| Genghini, S | 1 |
| Morselli-Labate, AM | 2 |
| Ajossa, S | 1 |
| Guerriero, S | 1 |
| Paoletti, AM | 1 |
| Orrù, M | 1 |
| Melis, GB | 1 |
| Vrbíková, J | 1 |
| Hill, M | 1 |
| Dvoráková, K | 1 |
| Stanická, S | 1 |
| Vondra, K | 1 |
| Stárka, L | 1 |
| Patton, L | 1 |
| Vaccina, A | 1 |
| Cavazza, C | 1 |
| deKernion, JB | 1 |
| Diamanti-Kandarakis, E | 2 |
| Mitrakou, A | 2 |
| Hennes, MM | 1 |
| Platanissiotis, D | 1 |
| Kaklas, N | 1 |
| Spina, J | 1 |
| Georgiadou, E | 1 |
| Hoffmann, RG | 1 |
| Kissebah, AH | 1 |
| Raptis, S | 2 |
| Tolis, G | 1 |
| Duleba, AJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multi-center, Prospective, Cohort Study to Elucidate the Effects of Metformin Treatment on Steroid Hormones and Social Behavior. Linking Autistic Behaviorial Symptoms to Changes in Steroid Hormone Availability[NCT04930471] | 45 participants (Anticipated) | Observational | 2021-06-30 | Not yet recruiting | |||
| Metabolic Syndrome in PCOS: Precursors and Interventions[NCT00442689] | 97 participants (Actual) | Interventional | 2006-07-31 | Completed | |||
| Pilot Trial of Bicalutamide Versus Placebo in Reproductive-Aged Women With Nonalcoholic Fatty Liver Disease (NAFLD) and Polycystic Ovary Syndrome (PCOS)[NCT05979389] | Phase 1 | 50 participants (Anticipated) | Interventional | 2023-12-31 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Change in disposition index (DI, insulin secretion corrected for insulin secretion) as measured by frequently-sampled IV glucose tolerance test (DI at study endpoint - baseline DI) (NCT00442689)
Timeframe: 6 months
| Intervention | min^-1 (Mean) |
|---|---|
| Oral Contraceptive - 1 | 1653 |
| Flutamide - 2 | 194 |
| Placebo - 3 | -184 |
Change in fat percentage as measured by DEXA scan over the study period (Fat percentage at study endpoint - baseline fat percentage) (NCT00442689)
Timeframe: 6 months
| Intervention | percentage of body mass (Mean) |
|---|---|
| Oral Contraceptive - 1 | 0.4 |
| Flutamide - 2 | -1.9 |
| Placebo - 3 | -1.9 |
Change in high-density lipoprotein (HDL) levels during study period (HDL level at study endpoint - baseline HDL) (NCT00442689)
Timeframe: 6 months
| Intervention | mg/dL (Mean) |
|---|---|
| Oral Contraceptive - 1 | 6 |
| Flutamide - 2 | -5 |
| Placebo - 3 | -2 |
Change in low-density lipoprotein (LDL) levels over the study period (LDL level at study endpoint - baseline LDL level) (NCT00442689)
Timeframe: 6 months
| Intervention | mg/dL (Mean) |
|---|---|
| Oral Contraceptive - 1 | -6 |
| Flutamide - 2 | -9 |
| Placebo - 3 | -7 |
Change in maximal aerobic exercise capacity (VO2 max) over the study period (VO2 max at study endpoint - baseline VO2 max) (NCT00442689)
Timeframe: 6 months
| Intervention | L/min (Mean) |
|---|---|
| Oral Contraceptive - 1 | -0.5 |
| Flutamide - 2 | -1.6 |
| Placebo - 3 | 1.1 |
Change in resting energy expenditure (REE) over the study period (REE at study endpoint - baseline REE) (NCT00442689)
Timeframe: 6 months
| Intervention | Kcal/day (Mean) |
|---|---|
| Oral Contraceptive - 1 | 7 |
| Flutamide - 2 | -79 |
| Placebo - 3 | -88 |
Change in visceral adipose tissue (VAT) volume as measured by MRI (VAT at study endpoint - baseline VAT) (NCT00442689)
Timeframe: 6 months
| Intervention | L (Mean) |
|---|---|
| Oral Contraceptive - 1 | -0.1 |
| Flutamide - 2 | -0.1 |
| Placebo - 3 | 0.1 |
5 trials available for flutamide and Obesity
| Article | Year |
|---|---|
Anti-androgen treatment increases circulating ghrelin levels in obese women with polycystic ovary syndrome.
Topics: Adult; Androgen Antagonists; Androstenedione; Blood Glucose; Body Composition; Body Weight; Female; | 2003 |
Effect of flutamide and metformin administered alone or in combination in dieting obese women with polycystic ovary syndrome.
Topics: Adult; Analysis of Variance; Androgen Antagonists; Combined Modality Therapy; Diet, Reducing; Drug T | 2004 |
Effect of flutamide and metformin administered alone or in combination in dieting obese women with polycystic ovary syndrome.
Topics: Adult; Analysis of Variance; Androgen Antagonists; Combined Modality Therapy; Diet, Reducing; Drug T | 2004 |
Effect of flutamide and metformin administered alone or in combination in dieting obese women with polycystic ovary syndrome.
Topics: Adult; Analysis of Variance; Androgen Antagonists; Combined Modality Therapy; Diet, Reducing; Drug T | 2004 |
Effect of flutamide and metformin administered alone or in combination in dieting obese women with polycystic ovary syndrome.
Topics: Adult; Analysis of Variance; Androgen Antagonists; Combined Modality Therapy; Diet, Reducing; Drug T | 2004 |
Flutamide-metformin plus an oral contraceptive (OC) for young women with polycystic ovary syndrome: switch from third- to fourth-generation OC reduces body adiposity.
Topics: Abdomen; Adipose Tissue; Adolescent; Adult; Androgen Antagonists; Contraceptives, Oral; Drug Therapy | 2004 |
Treatment with flutamide, metformin, and their combination added to a hypocaloric diet in overweight-obese women with polycystic ovary syndrome: a randomized, 12-month, placebo-controlled study.
Topics: Adipose Tissue; Adult; Diet, Reducing; Drug Therapy, Combination; Energy Intake; Female; Flutamide; | 2006 |
Treatment with flutamide, metformin, and their combination added to a hypocaloric diet in overweight-obese women with polycystic ovary syndrome: a randomized, 12-month, placebo-controlled study.
Topics: Adipose Tissue; Adult; Diet, Reducing; Drug Therapy, Combination; Energy Intake; Female; Flutamide; | 2006 |
Treatment with flutamide, metformin, and their combination added to a hypocaloric diet in overweight-obese women with polycystic ovary syndrome: a randomized, 12-month, placebo-controlled study.
Topics: Adipose Tissue; Adult; Diet, Reducing; Drug Therapy, Combination; Energy Intake; Female; Flutamide; | 2006 |
Treatment with flutamide, metformin, and their combination added to a hypocaloric diet in overweight-obese women with polycystic ovary syndrome: a randomized, 12-month, placebo-controlled study.
Topics: Adipose Tissue; Adult; Diet, Reducing; Drug Therapy, Combination; Energy Intake; Female; Flutamide; | 2006 |
Insulin sensitivity and antiandrogenic therapy in women with polycystic ovary syndrome.
Topics: Adolescent; Adult; Androgen Antagonists; Androgens; Female; Flutamide; Humans; Insulin Resistance; O | 1995 |
7 other studies available for flutamide and Obesity
| Article | Year |
|---|---|
Hyperinsulinaemic androgen excess in adolescent girls.
Topics: Adolescent; Androgens; Drug Therapy, Combination; Dyslipidemias; Female; Flutamide; Hirsutism; Human | 2014 |
Developmental Programming: Impact of Gestational Steroid and Metabolic Milieus on Adiposity and Insulin Sensitivity in Prenatal Testosterone-Treated Female Sheep.
Topics: Adiposity; Animals; Disease Models, Animal; Embryonic Development; Female; Flutamide; Insulin Resist | 2016 |
Modulation of ovarian structure and abdominal obesity in curcumin- and flutamide-treated aging FSH-R haploinsufficient mice.
Topics: Abdominal Fat; Aging; Animals; Curcumin; Female; Flutamide; Haploidy; Mice; Mice, Transgenic; Obesit | 2009 |
The treatment of polycystic ovary syndrome.
Topics: Adult; Androgen Antagonists; Cabergoline; Cardiovascular Diseases; Clomiphene; Cyproterone Acetate; | 2004 |
Flutamide suppresses adrenal steroidogenesis but has no effect on insulin resistance and secretion and lipid levels in overweight women with polycystic ovary syndrome.
Topics: 17-Hydroxysteroid Dehydrogenases; Adrenal Glands; Adrenocorticotropic Hormone; Adult; Androgen Antag | 2004 |
Prostate cancer.
Topics: Androgen Antagonists; Antineoplastic Agents; Chemotherapy, Adjuvant; Flutamide; Humans; Male; Obesit | 1996 |
The effect of a pure antiandrogen receptor blocker, flutamide, on the lipid profile in the polycystic ovary syndrome.
Topics: Adult; Androgen Antagonists; Androstane-3,17-diol; Androstenedione; Cholesterol; Dehydroepiandroster | 1998 |